Studies in solid tumor models provided some evidence of using propranolol as a chemo‐ or radio‐sensitizer [22, 37], or to improve the outcome of cancer immunotherapies (e.g. anti‐CTLA4 therapy) [38]. This evidence concerns the gene CTLA4 and cancer.